Last reviewed · How we verify
Dorsiflex (MEPHENOXALONE)
Dorsiflex (generic name: MEPHENOXALONE) is a mephenoxalone drug. It is currently in Phase 2 development.
Dorsiflex works by interacting with a specific target in the body to produce its therapeutic effect.
Dorsiflex is a small molecule modality. It has been studied in clinical trials for various conditions, including Heel Pain Syndrome, Restless Leg Syndrome, and Sleep Disturbance, using interventions such as acupuncture and manual therapy.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MEPHENOXALONE |
|---|---|
| Drug class | mephenoxalone |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Unfortunately, the exact mechanism of action of Dorsiflex is not well understood, but it is thought to involve the modulation of neural activity to produce its effects. This can lead to changes in the way the brain processes information and responds to stimuli. More research is needed to fully understand how Dorsiflex works.
Approved indications
Common side effects
Key clinical trials
- The Effect of Quadriceps Sets Exercise on Knee Joint Biomechanics and Functional Outcomes of Post-Total Knee Arthroplasty Patients (NA)
- Randomized Controlled Trial of Custom Foot Orthoses for Chronic Forefoot Pain (NA)
- Progressive Inhibition of Neuromuscular Structure and Neural Tissue Mobilization. (NA)
- Clinical Effects of Moxibustion Combined With Tailored Baduanjin Exercise Programs on Early Postoperative Rehabilitation in Lumbar Disc Herniation Patients Undergoing Minimally Invasive Surgery (NA)
- A Study Examining Changes in Pain After Manual Therapy in People With Achilles Tendon Pain (NA)
- Comparative Effects of Sciatic Nerve Flossing and Active Release Technique in Cyclists With Sciatica (NA)
- Effects of PNF Stretching vs Conventional Physical Therapy on the Symptoms of Restless Leg Syndrome in Elderly Population. (NA)
- Metatarsal Phalangeal Joint Deformity Progression - R01 (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dorsiflex CI brief — competitive landscape report
- Dorsiflex updates RSS · CI watch RSS
Frequently asked questions about Dorsiflex
What is Dorsiflex?
How does Dorsiflex work?
What is the generic name of Dorsiflex?
What drug class is Dorsiflex in?
What development phase is Dorsiflex in?
Related
- Drug class: All mephenoxalone drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing